AAHKS临床研究奖:全膝关节置换术前一年膝骨关节炎的花费是多少?
基于Humana数据库2007至2015年86,081例初次全膝关节置换(TKA)患者,统计TKA前一年膝骨关节炎非关节置换治疗费用并按美国骨科医师学会(AAOS)临床实践指南(CPG)推荐状态分层。结果显示65.8%患者至少接受过一种治疗,所分析治疗占TKA前一年膝骨关节炎非住院总费用的57.6%,其中仅玻璃酸(HA)注射一项即占29.3%,而CPG强烈推荐的3种治疗仅占12.2%。
要点
- TKA前一年65.8%的患者至少接受过一种非关节置换治疗。
- 所分析治疗占膝骨关节炎非住院总费用的57.6%,仅HA注射即占29.3%。
- CPG强烈推荐的3种治疗(物理治疗、非甾体抗炎药、曲马多)仅占非住院费用的12.2%。
核心结论
- TKA前一年,膝骨关节炎非住院费用的一半以上来自注射、治疗、矫形器和处方。
- 其中约30%仅来自HA注射,若仅使用CPG推荐的干预,膝骨关节炎相关费用可降低45%。
研究设计与样本
- 回顾性分析Humana数据库2007至2015年86,081例初次TKA患者。
- 统计TKA前一年HA与皮质类固醇注射、物理治疗、支具、楔形鞋垫、阿片类、非甾体抗炎药和曲马多的费用,费用定义为保险支付方支付的报销金额。
- 费用按膝骨关节炎非住院总费用分析并依据CPG推荐状态分类。
主要发现
- 86,081例初次TKA患者中65.8%在TKA前一年至少接受过一种治疗。
- 所分析治疗占TKA前一年膝骨关节炎非住院总费用的57.6%。
- 8种治疗中仅3种(物理治疗、非甾体抗炎药、曲马多)有强烈推荐,其费用占非住院膝骨关节炎费用的12.2%。
- HA注射一项即占费用的29.3%,而HA注射不受CPG支持。
关键数值与推荐
- 8种治疗中仅物理治疗、非甾体抗炎药、曲马多3种有CPG强烈推荐,费用占非住院膝骨关节炎费用的12.2%。
- HA注射占非住院膝骨关节炎费用的29.3%,不受CPG支持。
- 若仅使用CPG推荐的干预,膝骨关节炎相关费用可降低45%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite American Academy of Orthopaedic Surgeons Clinical Practice Guidelines (CPGs) related to the non-arthroplasty management of osteoarthritis (OA) of the knee, non-recommended treatments remain in common use. We sought to determine the costs associated with non-arthroplasty management of knee OA in the year prior to total knee arthroplasty (TKA) and stratify them by CPG recommendation status. METHODS: The Humana database was reviewed from 2007 to 2015 for primary TKA patients. Costs for hyaluronic acid (HA) and corticosteroid injections, physical therapy, braces, wedge insoles, opioids, non-steroidal anti-inflammatories, and tramadol in the year prior to TKA were calculated. Cost was defined as reimbursement paid by the insurance provider. Costs were analyzed relative to the overall non-inpatient costs for knee OA and categorized based on CPG recommendations. RESULTS: In total 86,081 primary TKA patients were analyzed and 65.8% had at least one treatment in the year prior to TKA. Treatments analyzed made up 57.6% of the total non-inpatient cost of knee OA in the year prior to TKA. Only 3 of the 8 treatments studied have a strong recommendation for their use (physical therapy, non-steroidal anti-inflammatories, tramadol) and costs for these interventions represented 12.2% of non-inpatient knee OA cost. In contrast, 29.3% of the costs are due to HA injections alone, which are not supported by CPGs. CONCLUSION: In the year prior to TKA, over half of the non-inpatient costs associated with knee OA are from injections, therapy, prosthetics, and prescriptions. Approximately 30% of this is due to HA injections alone. If only interventions recommend by the CPG are utilized then costs associated with knee OA could be decreased by 45%.
引用
- Bedard NA, Dowdle SB, Anthony CA, et al. The AAHKS Clinical Research Award: What Are the Costs of Knee Osteoarthritis in the Year Prior to Total Knee Arthroplasty? J Arthroplasty. 2017. PMID: 28209276. doi:10.1016/j.arth.2017.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。